Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095
Jeffrey T Schouten, Amy Krambrink, Heather J Ribaudo, Anne Kmack, Nancy Webb, Cecilia Shikuma, Daniel R Kuritzkes, Roy M Gulick, Jeffrey T Schouten, Amy Krambrink, Heather J Ribaudo, Anne Kmack, Nancy Webb, Cecilia Shikuma, Daniel R Kuritzkes, Roy M Gulick
Abstract
In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 .
Conflict of interest statement
Potential conflicts of interest. D.R.K. has served as a consultant for and has received speaker’s fees and research support from Boehringer-Ingelheim, Bristol-Myers Squibb, and GlaxoSmithKline. R.M.G. has received research grants (awarded to Cornell University) from Merck and has served as an ad hoc consultant to Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, and Merck. All other authors: no conflicts.
Figures
Source: PubMed